• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过流速调节进行静脉给药的体内药代动力学模型的体外模拟

In vitro simulation of in vivo pharmacokinetic model with intravenous administration via flow rate modulation.

作者信息

Chen Yuan-Cheng, Liang Wang, Hu Jia-Li, He Gao-Li, Wu Xiao-Jie, Liu Xiao-Fang, Zhang Jing, Hu Xue-Qian

机构信息

Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, China.

出版信息

J Pharmacokinet Pharmacodyn. 2015 Feb;42(1):33-43. doi: 10.1007/s10928-014-9396-7. Epub 2014 Oct 30.

DOI:10.1007/s10928-014-9396-7
PMID:25354895
Abstract

The aim of this paper was to propose a method of flow rate modulation for simulation of in vivo pharmacokinetic (PK) model with intravenous injection based on a basic in vitro PK model. According to the rule of same relative change rate of concentration per unit time in vivo and in vitro, the equations for flow rate modulation were derived using equation method. Four examples from literature were given to show the application of flow rate modulation in the simulation of PK model of antimicrobial agents in vitro. Then an experiment was performed to confirm the feasibility of flow rate modulation method using levo-ornidazole as an example. The accuracy and precision of PK simulations were evaluated using average relative deviation (ARD), mean error and root mean squared error. In vitro model with constant flow rate could mimic one-compartment model, while the in vitro model with decreasing flow rate could simulate the linear mammillary model with multiple compartments. Zero-order model could be simulated using the in vitro model with elevating flow rate. In vitro PK model with gradually decreasing flow rate reproduced the two-compartment kinetics of levo-ornidazole quite well. The ARD was 0.925 % between in vitro PK parameters and in vivo values. Results suggest that various types of PK model could be simulated using flow rate modulation method without modifying the structure. The method provides uniform settings for the simulation of linear mammillary model and zero-order model based on in vitro one-compartment model, and brings convenience to the pharmacodynamic study.

摘要

本文旨在基于基础体外药代动力学(PK)模型,提出一种用于模拟静脉注射体内PK模型的流速调节方法。根据体内和体外单位时间内浓度相对变化率相同的规律,采用方程法推导了流速调节方程。给出了文献中的四个实例,以展示流速调节在体外抗菌药物PK模型模拟中的应用。然后以左旋奥硝唑为例进行实验,以证实流速调节方法的可行性。使用平均相对偏差(ARD)、平均误差和均方根误差评估PK模拟的准确性和精密度。恒流速体外模型可模拟单室模型,而流速降低的体外模型可模拟多室线性乳突模型。使用流速升高的体外模型可模拟零级模型。流速逐渐降低的体外PK模型很好地再现了左旋奥硝唑的双室动力学。体外PK参数与体内值之间的ARD为0.925%。结果表明,无需修改结构,使用流速调节方法可模拟各种类型的PK模型。该方法为基于体外单室模型模拟线性乳突模型和零级模型提供了统一设置,为药效学研究带来了便利。

相似文献

1
In vitro simulation of in vivo pharmacokinetic model with intravenous administration via flow rate modulation.通过流速调节进行静脉给药的体内药代动力学模型的体外模拟
J Pharmacokinet Pharmacodyn. 2015 Feb;42(1):33-43. doi: 10.1007/s10928-014-9396-7. Epub 2014 Oct 30.
2
Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.非稳态研究中的药代动力学-药效学(PK-PD)建模及动静脉药物浓度差异
Br J Clin Pharmacol. 1994 Nov;38(5):389-400. doi: 10.1111/j.1365-2125.1994.tb04372.x.
3
A two-dimensional mathematical model of non-linear dual-sorption of percutaneous drug absorption.经皮药物吸收的非线性双吸附二维数学模型。
Biomed Eng Online. 2005 Jul 3;4:40. doi: 10.1186/1475-925X-4-40.
4
A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.一个关于结构模型参数估计对患者报告给药时间误差敏感性的药代动力学案例研究。
J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):627-37. doi: 10.1007/s10928-015-9428-y. Epub 2015 Jul 26.
5
Stereoselective pharmacokinetics of ornidazole after intravenous administration of individual enantiomers and the racemate.静脉注射奥硝唑对映体及外消旋体后的立体选择性药代动力学。
Chirality. 2006 Nov;18(10):799-802. doi: 10.1002/chir.20322.
6
Impact of saturable distribution in compartmental PK models: dynamics and practical use.房室药代动力学模型中可饱和分布的影响:动力学与实际应用
J Pharmacokinet Pharmacodyn. 2017 Feb;44(1):1-16. doi: 10.1007/s10928-016-9500-2. Epub 2017 Jan 3.
7
In vivo rat PK profiling in drug discovery: new challenges.在药物发现中的体内大鼠 PK 特征分析:新的挑战。
Expert Opin Drug Discov. 2010 Nov;5(11):1031-7. doi: 10.1517/17460441.2010.509396. Epub 2010 Jul 27.
8
Simultaneous optimal experimental design on dose and sample times.剂量与采样时间的同步优化实验设计
J Pharmacokinet Pharmacodyn. 2009 Apr;36(2):125-45. doi: 10.1007/s10928-009-9114-z. Epub 2009 Mar 25.
9
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.制药研究和制造商协会(PhRMA)与中国疾病预防控制中心(CPCDC)关于人类药代动力学预测模型的倡议,第4部分:使用和岛方法根据体内临床前数据预测人体血浆浓度-时间曲线
J Pharm Sci. 2011 Oct;100(10):4111-26. doi: 10.1002/jps.22551. Epub 2011 Apr 7.
10
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.制药研究和制造商协会(PHRMA)与美国疾病控制与预防中心(CPCDC)关于人体药代动力学预测模型的倡议,第5部分:使用基于生理学的药代动力学建模方法预测人体血浆浓度-时间曲线
J Pharm Sci. 2011 Oct;100(10):4127-57. doi: 10.1002/jps.22550. Epub 2011 May 3.

本文引用的文献

1
Combination therapy for Gram-negative bacteria: what is the evidence?革兰氏阴性菌的联合治疗:有哪些证据?
Expert Rev Anti Infect Ther. 2013 Dec;11(12):1355-62. doi: 10.1586/14787210.2013.846215. Epub 2013 Oct 30.
2
PK/PD models in antibacterial development.抗菌药物研发中的 PK/PD 模型。
Curr Opin Microbiol. 2013 Oct;16(5):573-9. doi: 10.1016/j.mib.2013.06.010. Epub 2013 Jul 18.
3
Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria.使用不同大小的目标细菌接种物进行替加环素药效学模拟的暴露-反应分析。
Int J Antimicrob Agents. 2010 Aug;36(2):137-44. doi: 10.1016/j.ijantimicag.2010.03.021. Epub 2010 May 11.
4
In vitro pharmacodynamic models to determine the effect of antibacterial drugs.体外药效动力学模型用于确定抗菌药物的作用。
J Antimicrob Chemother. 2010 Feb;65(2):186-201. doi: 10.1093/jac/dkp434. Epub 2009 Dec 21.
5
Effect of dosing interval on the efficacy of topical ophthalmic gatifloxacin against Enterococcus faecalis in an in vitro pharmacokinetic model simulating the local eye compartment.局部眼用药代动力学模型模拟研究中,不同滴眼间隔时间对局部应用加替沙星治疗粪肠球菌感染的疗效影响。
Int J Antimicrob Agents. 2009 Dec;34(6):561-5. doi: 10.1016/j.ijantimicag.2009.08.002. Epub 2009 Sep 25.
6
Development of an integrated semi-automated system for in vitro pharmacodynamic modelling.
J Antimicrob Chemother. 2008 Nov;62(5):1070-7. doi: 10.1093/jac/dkn294. Epub 2008 Jul 21.
7
Pharmacokinetics and pharmacodynamics of antimicrobials.抗菌药物的药代动力学和药效学
Clin Infect Dis. 2007 Jul 15;45 Suppl 1:S89-95. doi: 10.1086/518137.
8
Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.体外模型中影响对利奈唑胺耐药性出现的药代动力学/药效学因素。
Antimicrob Agents Chemother. 2007 Apr;51(4):1287-92. doi: 10.1128/AAC.01194-06. Epub 2007 Jan 22.
9
Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation.在体外药效学模型中,阿莫西林对非敏感肺炎链球菌的杀菌活性,该模型模拟了使用2000/125毫克缓释复方阿莫西林克拉维酸制剂所获得的浓度。
J Antimicrob Chemother. 2004 Dec;54(6):1148-51. doi: 10.1093/jac/dkh463. Epub 2004 Oct 15.
10
Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.他唑巴坦药代动力学对哌拉西林-他唑巴坦联合用药抗菌效果的影响。
Int J Antimicrob Agents. 2004 May;23(5):494-7. doi: 10.1016/j.ijantimicag.2003.10.012.